Plain-English translation of NCT07461545 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing apixaban, a blood-thinning medication, to see if it can help dissolve blood clots that develop in the portal vein after laparoscopic spleen removal surgery. The study focuses on patients who developed these clots more than one year after their surgery. Researchers will monitor how well the medication works using ultrasound and CT imaging every three months.
Portal vein clots that occur long after spleen removal surgery are a serious complication for patients with liver cirrhosis. Currently, there is limited information about the best way to treat these late-forming clots, so this trial aims to determine whether this medication is effective and safe for this specific situation.
You likely qualify if…
You likely don't qualify if…
You will take apixaban (a tablet) by mouth twice daily as your treatment. Every three months, you will have imaging tests—either an ultrasound or CT scan—to check whether the blood clot in your portal vein is improving. If the medication is working, you will continue taking it. The study will monitor you closely to make sure the treatment is safe and effective.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Sponsor
Northern Jiangsu People's Hospital
Enrollment target
~20 participants
Started
April 2026
Primary completion
September 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guo-Qing Jiang
Clinical Medical College, Yangzhou University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.